A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2

Climacteric

Volumn 11, Issue 6, 2008, Pages 447-453

  Bruce, D ^a,c   Frick, A ^a   Rymer, J ^a   Robinson, J ^a   Ylikorkala, O ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Camelot   (United Kingdom)

Author keywords

Hormone therapy; Prostacyclin; Thromboxane A2; Urinary excretion

Indexed keywords

ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; PLACEBO; PROSTACYCLIN; RALOXIFENE; THROMBOXANE A2; TIBOLONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HORMONAL THERAPY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; URINARY EXCRETION;

CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPOPROSTENOL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; RALOXIFENE; THROMBOXANE A2;

EID: 57349128384     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802387619     Document Type: Article

References (29)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11
2. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
3. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
5. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7
6. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005;66:295-306
7. Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 2005;84:1589-601
8. Mikkola TS, Ylikorkala O. Hormone therapy and cardiovascular disease - still much to be learnt. Gynecol Endocrinol 2005;20:116-20
9. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
10. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-602
11. Mendelsohn ME, Karas RH. HRT and the young at heart. N Engl J Med 2007;356:2639-41
12. Vane JR. Biomedicine. Back to an aspirin a day? Science 2002;296:474-5
13. Ruan K-H. Thrombogenesis and anti-thrombogenesis in atherosclerosis mediated by prostanoids through the cyclooxygenase pathway. In Geng YJ, ed. Current Topics in Atherosclerosis Research. New York: Nova Science Publishers Inc, 2005:81-102
14. Mueck AO, Seeger H. Biochemical markers surrogating on vascular effects of sex steroid hormones. Gynecol Endocrinol 2006;22:163-73
15. Mueck AO, Seeger H, Ludtke R, Graser T, Wallwiener D. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas 2001;38:305-13
16. Maffei S, Mercuri A, Prontera C, Zucchelli GC, Vassalle C. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy. Climacteric 2006;9:452-8
17. Mikkola T, Viinikka L, Ylikorkala O. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. Fertil Steril 2000;73:72-4
18. Viinikka L, Orpana A, Puolakka J, Pyorala T, Ylikorkala O. Different effects of oral and transdermal hormonal replacement on prostacyclin and thromboxane A2. Obstet Gynecol 1997;89:104-7
19. Ylikorkala O, Hirvonen E, Saure A, Viinikka L. Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: effect of estrogen-progestin replacement therapy. Prostaglandins 1990;39:33-7
20. Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinikka L, Toivonen J. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 1998;69:883-8
21. Oviedo PJ, Hermenegildo C, Cano A. Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2. Menopause 2004;11:430-7
22. Regitz-Zagrosek V, Wintermantel TM, Schubert C. Estrogens and SERMs in coronary heart disease. Curr Opin Pharmacol 2007;7:130-9
23. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21-8
24. Ylikorkala O, Pekonen F, Viinikka L. Renal prostacyclin and thromboxane in normotensive and preeclamptic pregnant women and their infants. J Clin Endocrinol Metab 1986;63:1307-12
25. Liang KY, Zeiger SL. Longitudinal analysis using generalised linear models. Biometrika 1986;73:13-22
26. Binder DA. On the variances of asymptomatically normal estimators from complex surveys. Int Statl Rev 1983;51:279-92
27. Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause 2007;14:978-84
28. Battaglia C, Mancini F, Persico N, et al. Tibolone, oral or transdermal hormone replacement and colour Doppler analysis: a prospective, randomised pilot study. Maturitas 2004;48:446-55
29. Oviedo PJ, Hermenegildo C, Tarin JJ, Cano A. Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2. Fertil Steril 2005;83:1822-9